SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Nerea Alonso, Dinesh C Soares, Eugene V McCloskey, Gregory D Summers, Stuart H Ralston, Celia L Gregson, Atypical Femoral Fracture in Osteoporosis Pseudoglioma Syndrome Associated with Two Novel Compound Heterozygous Mutations in LRP5, Journal of Bone and Mineral Research, 2015, 30, 4
  2. 2
    Robert Brommage, Genetic Approaches To Identifying Novel Osteoporosis Drug Targets, Journal of Cellular Biochemistry, 2015, 116, 10
  3. 3
    Wafa Bouaziz, Thomas Funck-Brentano, Hilène Lin, Caroline Marty, Hang-Korng Ea, Eric Hay, Martine Cohen-Solal, Loss of sclerostin promotes osteoarthritis in mice via β-catenin-dependent and -independent Wnt pathways, Arthritis Research & Therapy, 2015, 17, 1, 24

    CrossRef

  4. 4
    N. Lara-Castillo, M. L. Johnson, LRP receptor family member associated bone disease, Reviews in Endocrine and Metabolic Disorders, 2015, 16, 2, 141

    CrossRef

  5. 5
    Laura L. Tosi, Matthew L. Warman, Mechanistic and therapeutic insights gained from studying rare skeletal diseases, Bone, 2015, 76, 67

    CrossRef

  6. 6
    Barbara C Silva, John P Bilezikian, Parathyroid hormone: anabolic and catabolic actions on the skeleton, Current Opinion in Pharmacology, 2015, 22, 41

    CrossRef

  7. 7
    Maude Gerbaix, Laurence Vico, Serge L. Ferrari, Nicolas Bonnet, Periostin expression contributes to cortical bone loss during unloading, Bone, 2015, 71, 94

    CrossRef

  8. 8
    Cyril Thouverey, Joseph Caverzasio, Sclerostin inhibits osteoblast differentiation without affecting BMP2/SMAD1/5 or Wnt3a/β-catenin signaling but through activation of platelet-derived growth factor receptor signaling in vitro, BoneKEy Reports, 2015, 4, 757

    CrossRef

  9. 9
    Timur A Yorgan, Stephanie Peters, Anke Jeschke, Peggy Benisch, Franz Jakob, Michael Amling, Thorsten Schinke, The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5, Journal of Bone and Mineral Research, 2015, 30, 7
  10. 10
    Barbara C. Silva, John P. Bilezikian, The Parathyroids, 2015,

    CrossRef

  11. 11
    Rafael Velázquez-Cruz, Rogelio F Jiménez-Ortega, Alma Y Parra-Torres, Manuel Castillejos-López, Nelly Patiño, Manuel Quiterio, Teresa Villarreal-Molina, Jorge Salmerón, Analysis of association of MEF2C, SOST and JAG1 genes with bone mineral density in Mexican-Mestizo postmenopausal women, BMC Musculoskeletal Disorders, 2014, 15, 1, 400

    CrossRef

  12. 12
    Ming-Kang Chang, Ina Kramer, Thomas Huber, Bernd Kinzel, Sabine Guth-Gundel, Olivier Leupin, Michaela Kneissel, Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels, Proceedings of the National Academy of Sciences, 2014, 111, 48, E5187

    CrossRef

  13. 13
    Sandra Bermeo, Krishanthi Gunaratnam, Gustavo Duque, Fat and Bone Interactions, Current Osteoporosis Reports, 2014, 12, 2, 235

    CrossRef

  14. 14
    Bart O Williams, Insights Into the Mechanisms of Sclerostin Action in Regulating Bone Mass Accrual, Journal of Bone and Mineral Research, 2014, 29, 1
  15. 15
    Igor Fijalkowski, Eveline Boudin, Geert Mortier, Wim Van Hul, Sclerosing Bone Dysplasias: Leads Toward Novel Osteoporosis Treatments, Current Osteoporosis Reports, 2014, 12, 3, 243

    CrossRef

  16. 16
    Zhendong Zhong, Nicole J. Ethen, Bart O. Williams, WNT signaling in bone development and homeostasis, Wiley Interdisciplinary Reviews: Developmental Biology, 2014, 3, 6